Glenmark Pharma vs Gland Pharma vs Emcure Pharma: Which Stock Should You Track

Glenmark Pharmaceuticals vs Gland Pharma vs Emcure Pharmaceuticals starts with the core numbers most investors compare within the Pharma Formulations segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.

All three names sit in the Pharma Formulations bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.

Click Here – Get Free Investment Predictions

Glenmark Pharmaceuticals, Gland Pharma and Emcure Pharmaceuticals: Company Overview

Glenmark Pharmaceuticals is a listed Indian company in the Pharma Formulations space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Gland Pharma is a listed Indian company in the Pharma Formulations space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Emcure Pharmaceuticals is a listed Indian company in the Pharma Formulations space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Glenmark Pharmaceuticals vs Gland Pharma vs Emcure Pharmaceuticals: Valuation and Profitability Snapshot

Metric	Glenmark Pharmaceuticals	Gland Pharma	Emcure Pharmaceuticals
Market Cap (approx.)	Rs 67,254 crore	Rs 48,107 crore	Rs 36,902 crore
PE Ratio (TTM)	37.41	42.62	36.22
PB Ratio	6.40	4.64	7.45
Return on Equity (ROE)	28.08%	9.92%	18.67%
EPS (TTM, Rs)	63.70	68.41	53.71
Dividend Yield	0.21%	0.69%	0.18%
Debt to Equity	0.06	0.03	0.31
Book Value per Share (Rs)	372.47	627.71	260.93

Check the Univest Screener for Live Data

On valuation, Glenmark Pharmaceuticals trades at a PE of 37.41 and a PB of 6.40, Gland Pharma at a PE of 42.62 and a PB of 4.64, while Emcure Pharmaceuticals trades at a PE of 36.22 and a PB of 7.45. On return on equity, the three post 28.08%, 9.92% and 18.67% respectively, and on dividend yield they stand at 0.21%, 0.69% and 0.18%.

Glenmark Pharmaceuticals vs Gland Pharma vs Emcure Pharmaceuticals: Latest Quarterly Results

Company	Latest Quarter Revenue	Latest Quarter Net Profit	YoY Change (Revenue)	QoQ Change (Revenue)
Glenmark Pharmaceuticals	Rs 4,084.24 crore	Rs 482.83 crore	+24.1%	+3.1%
Gland Pharma	Rs 1,861.50 crore	Rs 316.96 crore	+19.1%	+0.4%
Emcure Pharmaceuticals	Rs 2,582.52 crore	Rs 292.49 crore	+22.7%	+4.4%

Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter.

Download the Univest iOS App or Univest Android App to track Glenmark Pharmaceuticals, Gland Pharma and Emcure Pharmaceuticals live prices.

What Should Investors Look at Beyond These Numbers?

Beyond the metrics above, investors comparing these three pharma formulations names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and any sector-specific regulatory developments, since a single-quarter snapshot can shift quickly.

Conclusion

Glenmark Pharmaceuticals vs Gland Pharma vs Emcure Pharmaceuticals highlights how differently three companies in the same pharma formulations segment can score across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.

FAQs on Glenmark Pharmaceuticals vs Gland Pharma vs Emcure Pharmaceuticals

What is the market cap difference between Glenmark Pharmaceuticals, Gland Pharma and Emcure Pharmaceuticals?

Ans. As of September 2026, Glenmark Pharmaceuticals has a market cap of approximately Rs 67,254 crore, Gland Pharma is at approximately Rs 48,107 crore, and Emcure Pharmaceuticals is at approximately Rs 36,902 crore.

Which of the three has the highest PE ratio?

Ans. Among Glenmark Pharmaceuticals, Gland Pharma and Emcure Pharmaceuticals, the PE ratios stand at 37.41, 42.62 and 36.22 respectively as of September 2026.

Which of the three has the highest ROE?

Ans. Glenmark Pharmaceuticals, Gland Pharma and Emcure Pharmaceuticals post ROE of 28.08%, 9.92% and 18.67% respectively as of September 2026.

Which of these three stocks pays the highest dividend yield?

Ans. Glenmark Pharmaceuticals, Gland Pharma and Emcure Pharmaceuticals carry dividend yields of 0.21%, 0.69% and 0.18% respectively.

What is the debt to equity ratio for Glenmark Pharmaceuticals, Gland Pharma and Emcure Pharmaceuticals?

Ans. Glenmark Pharmaceuticals carries a debt to equity of 0.06, Gland Pharma of 0.03, and Emcure Pharmaceuticals of 0.31.

Which of the three trades at the highest price to book value?

Ans. Glenmark Pharmaceuticals, Gland Pharma and Emcure Pharmaceuticals trade at price to book ratios of 6.40, 4.64 and 7.45 respectively.

Is one of Glenmark Pharmaceuticals, Gland Pharma or Emcure Pharmaceuticals better than the others?

Ans. This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research.